10q10k10q10k.net
GeoVax Labs, Inc.

GeoVax Labs, Inc.GOVXEarnings & Financial Report

Nasdaq

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara (MVA) vector technology, with improvements to antigen design and manufacturing capabilities. GeoVax uses recombinant DNA or recombinant viruses to produce virus-like particles (VLPs) in the person being vaccinated.

NextMar 27, 2026

GOVX Q3 2025 Key Financial Metrics

Revenue

$0

Gross Profit

N/A

Operating Profit

$-6.4M

Net Profit

$-6.3M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-0.31

GeoVax Labs, Inc. Q3 2025 Financial Summary

GeoVax Labs, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-6.3M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$0
Net Profit$-6.3M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ3 2025

GeoVax Labs, Inc. Annual Revenue by Year

GeoVax Labs, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $4.0M).

YearAnnual Revenue
2024$4.0M
2023$0
2022$81.5K

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$0$0$300677$2.8M$864415$1.6M$852282$0
YoY GrowthN/AN/AN/AN/AN/AN/A183.5%N/A

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$9.3M$3.4M$4.1M$11.1M$8.2M$10.8M$5.4M$6.7M
LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Equity$5.8M$54275$-2.3M$8.5M$5.0M$7.9M$2.8M$4.9M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-10.3M$-5.7M$-1.9M$-9.3M$-7.8M$-6.0M$-4.3M$-6.2M